Cardiology in Missouri

Koven Technology is the exclusive North American supplier of Koven/Hadeco vascular Doppler systems and related products. Founded in 1981, the company specializes in noninvasive ultrasound vascular Dopplers for peripheral arterial disease diagnosis and monitoring, surgical Dopplers and probes for intraoperative vascular procedures, and fetal Dopplers for obstetric applications. Koven's product portfolio includes handheld and table-top systems, with recent offerings including the Smartdop XT and Smartdop XT6 vascular testing systems integrated with PAUS 2.0 modality worklist software. The company serves vascular surgeons, interventional radiologists, cardiologists, and obstetric clinicians across the United States, Canada, and the United Kingdom. Koven manufactures and distributes FDA-cleared medical devices designed for noninvasive evaluation of peripheral vascular disease and intraoperative vascular assessment. The company also provides product design consulting services through its subsidiary Koven Innovation and offers online Doppler training to support clinical implementation and operator certification.

Cardiovascular Imaging Technologies, LLC (CVIT) develops and distributes advanced cardiac imaging software solutions for PET and SPECT myocardial perfusion analysis. The company's flagship product, ImagenQ 3.0, is a quantitative myocardial blood flow analysis platform designed for rapid, automated processing of cardiac PET imaging data. ImagenQ 3.0 delivers end-to-end analysis in under 60 seconds with robust quality control tools including ROI assessment, splenic shut-off detection, and arterial input function curve analysis. The software supports multiple PET tracers (Rb-82, N-13 ammonia, F-18 flurpiridaz) and is compatible with most PET/CT systems and image review platforms. CVIT also supplies the Cedars Cardiac Suite, an established standard for PET and SPECT myocardial perfusion imaging. The company provides comprehensive technical support, clinical training, and research laboratory services to support clinical trial endpoints and advance nuclear cardiology imaging. CVIT maintains an in-house imaging core lab staffed by internationally recognized nuclear medicine professionals and operates a real-time support model emphasizing direct clinician access to technical expertise. The company serves hospital nuclear medicine departments, cardiovascular centers, and research institutions performing cardiac imaging and myocardial perfusion studies.

iRT Systems GmbH manufactures the Integral Quality Monitor (IQM) System, a real-time verification device for radiation therapy treatment delivery. The IQM System represents a paradigm shift in radiation therapy quality assurance by providing fully automated, real-time verification of complex treatment techniques without user intervention. The device integrates seamlessly into clinical workflows and performs independent verification of beam product quality and treatment plan delivery. IQM is designed to reduce quality assurance time while maintaining or exceeding the error detection capability of conventional 3D phantom-based methods. The system has been clinically evaluated at leading radiation oncology centers worldwide, including Johns Hopkins University, University of California at Davis, Princess Margaret Cancer Centre, and multiple European institutions. The device complies with EU regulatory requirements, including the 2013/59/EURATOM directive on radiation protection. iRT Systems serves radiation oncology departments and cancer centers globally, with reference sites across North America and Europe. The company actively participates in major oncology conferences including ESTRO, AAPM, DEGRO, and ICON, demonstrating commitment to clinical education and advancement of radiation therapy quality standards.

General Physiotherapy II LLC manufactures G5® brand electromechanical massage and percussion modalities, recognized globally as the most powerful, reliable, and durable therapeutic devices. With over 60 years of industry experience and more than 250,000 units sold worldwide, G5 devices are the standard equipment for respiratory therapists, physical therapists, chiropractors, sports medicine practitioners, and spa professionals. The company produces proprietary percussion technology featuring multidirectional movements and variable speed settings to deliver deep tissue massage and percussion without therapist fatigue. G5 devices are engineered with over-specified power supplies and motors designed for clinical longevity (with documented usage exceeding 20-40 years). Products are used across professional sports globally, including FIFA and NFL teams. The company operates manufacturing facilities in St. Louis, Missouri and Casteljaloux, France, distributing products worldwide. G5 modalities complement hands-on therapy techniques, improve patient outcomes, reduce pharmaceutical dependency, and enable therapists to treat more clients per session.

BioTAB Healthcare is a family-owned medical devices manufacturer established in 2003, specializing in clinically proven, FDA and CE-approved in-home compression therapy systems. The company addresses lymphatic, wound, and circulatory disorders including lymphedema, venous disease, and peripheral arterial disease (PAD). BioTAB's advanced compression devices are designed to reduce pain, restore circulation, and improve mobility for patients managing chronic vascular conditions. Products are manufactured in America and backed by a 6-year warranty. The company provides comprehensive patient support including healthcare provider coordination, insurance benefits verification, in-home garment fitting, equipment training, and ongoing clinical assistance. With approximately 84-205 employees, BioTAB operates in the B2B medical devices sector, serving healthcare systems, clinics, and individual patients requiring long-term compression therapy management.

Radialogica is a healthtech company specializing in radiation oncology quality management software and services. The company provides tools and services to evaluate, manage, and enhance the quality and safety of radiotherapy treatment planning and delivery for cancer patients. Radialogica operates in two primary business segments: Clinical Trials Services and Clinical Software Tools. In clinical trials, Radialogica partners with pharmaceutical sponsors, biotechnology companies, CROs, and medical device manufacturers to design and implement comprehensive radiotherapy quality assurance programs. Services include development of RT treatment guidelines, collection and aggregation of DICOM-RT treatment plan data, extraction and evaluation of dosimetric parameters, and prospective or retrospective case reviews. The company has processed over 10,000 radiotherapy case submissions across clinical and research projects, operating across 6 continents, 50+ countries, and 600+ clinical sites. Clinical software offerings include SciMoCa™, a Monte Carlo dose calculation and beam model verification platform for dose verification and plan quality evaluation, and fullAccess™, an integrated radiotherapy data display, communication, and analysis platform enabling multi-disciplinary access and sharing of RT data across the continuum of care. These tools have been deployed at over 225 clinical sites worldwide and have impacted quality of care for over 1.5 million patient treatments. Radialogica addresses the significant variability in treatment planning and delivery inherent in radiation oncology through software-enabled prospective quality review and data analytics. The company serves pharma trials, medical registries, payer benefits management, and provider quality benchmarking programs. All services leverage proprietary software tools and technology infrastructure purpose-built for RT data acquisition, processing, and analysis.

Curium is the world's leading radiopharmaceutical manufacturer and provider, delivering nuclear medicine solutions across diagnostic imaging and therapeutic applications. The company manufactures and distributes radiopharmaceuticals (SPECT and PET agents) used in oncology, cardiology, and neurology imaging. Curium operates a global network of 4 manufacturing facilities, 1 molybdenum-99 processing plant, 45+ radiopharmacies, and 6,000+ customer locations across 70+ countries, serving approximately 15 million patients annually. The company maintains 100+ years of combined industry heritage and operates multiple regional headquarters and manufacturing centers including facilities in Maryland Heights (MO) and Noblesville (IN) in the United States, as well as production sites in Finland, the Netherlands, France, and Austria. Curium's portfolio includes 50+ radiopharmaceutical products for PET and SPECT imaging. The organization employs 5,000+ skilled professionals and maintains a commitment to quality, innovation, and service reliability. Regulatory compliance and manufacturing standards align with international requirements for pharmaceutical and medical device production in nuclear medicine.

SafER Medical Products manufactures the SafER Portable Negative Pressure System, a portable negative air containment solution designed to limit transmission of airborne contaminants during respiratory treatments and emergency procedures. Developed by emergency room physicians and firefighters, the system enables healthcare facilities and emergency responders to create negative pressure isolation environments in any setting—ambulances, emergency departments, clinics, and field operations—without requiring fixed infrastructure. FDA and CE marked, the system has demonstrated approximately 99% effectiveness in removing exhaled particles from the work environment via CFD analysis. The device is highly portable, accessible, and affordable compared to traditional hospital-based negative pressure isolation rooms, making it suitable for critical care, EMS transport, emergency response, and respiratory therapy applications.

MediBeacon Inc. is a medical technology company specializing in fluorescent tracer agents and transdermal detection technology for non-invasive physiological monitoring. The company's proprietary platform enables real-time measurement and monitoring of vital organ function through biocompatible fluorescent agents that are sensed through the skin via transdermal optical sensors. Primary clinical focus areas include nephrology (kidney function assessment via transdermal GFR measurement), gastroenterology (gut barrier permeability assessment), ophthalmology (fluorescent angiography for retinal vasculature visualization), and surgical applications (intraoperative visualization and identification of anatomical structures). MediBeacon's Transdermal GFR (TGFR) System received FDA PMA approval (P230019) and CE Mark for human clinical use. The company serves leading academic medical centers, research institutes, contract research organizations (CROs), and pharmaceutical companies globally for both preclinical research and clinical applications. MediBeacon maintains offices in St. Louis, Missouri (USA), Mannheim, Germany, and partnerships in Greater China through Huadong Medicine Co., Ltd.